Study wrapper · #890
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
Aroda VR, Buzzetti R, Dalskov SM, et al. The lancet. Diabetes & endocrinology. 2026.
DOI: 10.1016/s2213-8587(26)00126-9PubMed: 42251860
Editor's note
This placebo-controlled phase 3a RCT tested cagrilintide-semaglutide in early type 2 diabetes, showing large HbA1c and weight reductions versus placebo. Semaglutide is a core component, though effects reflect the combination rather than semaglutide alone. The trial was Novo Nordisk-funded and placebo-controlled rather than compared to semaglutide monotherapy, so the isolated semaglutide contribution is not separable here.
Plain-language abstract
In this phase 3a trial, the cagrilintide-semaglutide combination lowered HbA1c by up to 1.8 points and reduced body weight by about 14% versus placebo in adults with early type 2 diabetes.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026